BSE Live
Jan 28, 16:01Prev. Close
756.75
Open Price
757.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 28, 15:58Prev. Close
757.30
Open Price
770.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
763.70 (8)
| Key Financial Ratios of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 | |
| Diluted EPS (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 60.81 | |
| Cash EPS (Rs.) | 43.74 | 45.25 | 32.99 | 40.83 | 66.05 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 | |
| Revenue from Operations/Share (Rs.) | 339.46 | 316.90 | 287.59 | 269.95 | 274.39 | |
| PBDIT/Share (Rs.) | 53.46 | 48.93 | 36.18 | 47.04 | 79.75 | |
| PBIT/Share (Rs.) | 39.29 | 35.05 | 22.17 | 32.45 | 70.42 | |
| PBT/Share (Rs.) | 35.94 | 32.20 | 19.61 | 31.55 | 69.60 | |
| Net Profit/Share (Rs.) | 29.57 | 31.38 | 18.97 | 26.24 | 56.72 | |
| NP After MI And SOA / Share (Rs.) | 29.68 | 31.33 | 17.40 | 26.50 | 59.94 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 15.74 | 15.43 | 12.58 | 17.42 | 29.06 | |
| PBIT Margin (%) | 11.57 | 11.06 | 7.70 | 12.02 | 25.66 | |
| PBT Margin (%) | 10.58 | 10.15 | 6.82 | 11.68 | 25.36 | |
| Net Profit Margin (%) | 8.71 | 9.90 | 6.59 | 9.71 | 20.67 | |
| NP After MI And SOA Margin (%) | 8.74 | 9.88 | 6.05 | 9.81 | 21.84 | |
| Return on Networth/Equity (%) | 11.23 | 12.78 | 7.82 | 9.94 | 22.97 | |
| Return on Capital Employed (%) | 14.40 | 13.80 | 9.58 | 11.79 | 25.49 | |
| Return on Assets (%) | 7.50 | 9.55 | 5.53 | 7.31 | 17.56 | |
| Total Debt/Equity (X) | 0.23 | 0.09 | 0.15 | 0.12 | 0.04 | |
| Asset Turnover Ratio (%) | 0.94 | 0.99 | 0.78 | 0.73 | 80.38 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.69 | 2.12 | 1.78 | 1.67 | 2.01 | |
| Quick Ratio (X) | 0.75 | 0.99 | 0.88 | 0.73 | 0.85 | |
| Inventory Turnover Ratio (X) | 3.39 | 0.90 | 0.87 | 0.78 | 3.63 | |
| Dividend Payout Ratio (NP) (%) | 37.06 | 25.53 | 57.47 | 52.82 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 25.08 | 17.69 | 31.83 | 34.06 | 0.00 | |
| Earnings Retention Ratio (%) | 62.94 | 74.47 | 42.53 | 47.18 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 74.92 | 82.31 | 68.17 | 65.94 | 0.00 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 13.34 | 17.11 | 14.17 | 52.15 | 86.40 | |
| Interest Coverage Ratios (Post Tax) (%) | 13.34 | 17.11 | 14.17 | 52.15 | 86.40 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 19,368.46 | 19,611.97 | 10,301.50 | 15,131.79 | 19,003.45 | |
| EV/Net Operating Revenue (X) | 2.90 | 3.15 | 1.82 | 2.85 | 3.52 | |
| EV/EBITDA (X) | 18.43 | 20.39 | 14.49 | 16.37 | 12.12 | |
| MarketCap/Net Operating Revenue (X) | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 | |
| Retention Ratios (%) | 62.93 | 74.46 | 42.52 | 47.17 | 0.00 | |
| Price/BV (X) | 3.52 | 4.01 | 2.23 | 2.78 | 3.70 | |
| Price/Net Operating Revenue | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 | |
| Earnings Yield | 0.03 | 0.03 | 0.04 | 0.04 | 0.06 |
17.11.2025
Alembic Pharma shares gain 2% on USFDA nod for Diltiazem Hydrochloride tablets
17.11.2025
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct